We remove obstacles, move faster, and extend lives.

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by identical twin sisters Kathy Giusti and Karen Andrews soon after Kathy’s diagnosis of multiple myeloma. Kathy’s need was urgent. She was looking for a cure.

Finding that the current system was not optimized for speed, she changed it.

The medical research model has long been built upon a system of competition for funding (grants) and accolades (publishing). This wasn't working well for Kathy Giusti. When she was diagnosed, no treatment had been developed for multiple myeloma in decades, and what was available wasn't very effective.

Kathy realized that the old model was a barrier to success, and encouraged individuals and companies to hoard their data and discoveries. She and her sister created the MMRF to replace this system with a new patient-centered model of collaboration.

Because our only motivation is to find a cure, we are unencumbered in our ability to identify the barriers to progress, develop models to overcome them, and help evolve the industry through technologies that foster collaboration and leverage the collective power of the entire community.

This powerful MMRF philosophy has been well-proven as the most efficient way to continually speed the development of more effective treatments for patients.

Our accomplishments include:

  • Establishing a multi-center tissue bank with more than 4,000 samples.
  • Spearheading an initiative to map the multiple myeloma genome with world-class leaders in genomics.
  • Creating the collaborative Multiple Myeloma Research Consortium (MMRC) of 21 world-renowned institutions.
  • Launching the groundbreaking CoMMpass℠ Study to collect and analyze multiple tissue samples from 1,000 patients over a multi-year course, so that patients will eventually be matched with the right clinical studies and treatments.
  • Building the CoMMunity Gateway, a platform to connect patients sharing sub-types of myeloma with each other and experts.

The results are impressive. Six drugs received FDA approval in the time it normally takes for one. More recently, we opened clinical trials for new drugs in three approved classes plus agents in many new classes.

As the world's number one private funder of multiple myeloma research, we have raised over $250 million since our inception. We direct nearly 90% of our total budget to research and related programming.

We are well-positioned to see new drug breakthroughs that will make a difference in patients' lives. And, in the process, we are changing the way cancer research is conducted.

  • 2014
  • Plan to open 10 new trials
  • 2014
  • 200 sequences from MMGI published in Cancer Cell
  • 2014
  • CoMMpass Study enrollment almost completed
  • 2014
  • MMRC launches 50th
    clinical trial
  • 2013
  • Kathy Giusti honored by the White House as an Open Science Champion of Change
  • 2013
  • CoMMunity and Researcher Gateways launched
  • 2013
  • Pomylast® approved
  • 2012
  • MMRF and US Dept. of Veterans Affairs create partnership
  • 2012
  • Krypolis® Approved
  • 2011
  • Kathy Giusti named to the
    Time 100 list
  • 2011
  • MMRF CoMMpass℠ launched
  • 2011
  • MMGI sequencing results published in Nature
  • 2010
  • MMRC enrolls 1,000th patient in a clinical trial
  • 2009
  • MMRC (IST) Platform built
  • 2009
  • MMRC accelerates trial opening by 60%
  • 2008
  • Doxil approved
  • 2007
  • Revlimid® approved
  • 2006
  • Thalomid® approved
  • 2005
  • MMGI launched
  • 2005
  • MMRF Biotech Awards launched
  • 2004
  • MMRC tissue bank established
  • 2004
  • MMRC founded
  • 2003
  • Kathy Giusti named to the National Cancer Advisory Board (NCAB)
  • 2003
  • Velcade® approved
  • 2002
  • MMRF Grants Program approved by NCI
  • 2002
  • Zometa® approved
  • 2000
  • First MMRF Program Grant awarded
  • 1999
  • First MMRF Research Roundtable
  • 1998
  • First MMRF Research Grant Awards
  • 1998
  • MMRF established

Trailblazing Initiatives

At the MMRF, we remove obstacles by inventing new ways to solve problems. The initiatives we have launched have helped accelerate the pace of treating and curing multiple myeloma — and are changing the paradigm of how all cancer research is conducted.

The MMRF CoMMpass Study
The MMRF CoMMpassSM Study

Launched in 2011, the MMRF CoMMpass Study will be collecting tissue samples from patients over a 10-year period before treatment, at confirmed remission, and at relapse, to identify new drug targets and understand the molecular and genetic changes underpinning the disease as it evolves — and eventually match sub-types to the right treatment.

LEARN MORE
The MMRF Researcher Gateway
The MMRF Researcher Gateway

The MMRF Researcher Gateway is a first-in-class, publicly shared database of clinical and molecular data never before made widely available for myeloma. It provides access to genomic and other information from the MMRF CoMMpass Study as it becomes available.

LEARN MORE
The MMRF CoMMunity Gateway
The MMRF CoMMunity Gateway

This online platform connects patients with various subtypes of myeloma to each other and experts, and helps them find appropriate trials. It enables patients to provide important, real-time feedback about therapeutic efficacy and quality of life on treatment that will inform better clinical decisions and patient care — and deepen our understanding of myeloma.

LEARN MORE
The MMRF Genomics Initiative
The MMRF Genomics Initiative

The most extensive research collaboration ever focused on the genomics of multiple myeloma, the MMGI collaboration was the first to map the multiple myeloma genome. The result, a centralized repository of high-quality genomic information and cutting-edge bioinformatics tools, has improved our ability to identify specific subtypes and design therapies to treat them.

LEARN MORE

Meet our Leadership Team

Get to know the uniquely talented and committed individuals whose hard work is leading us to more and better treatments, and a cure.

MEET THE TEAM